Skip to content

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

Pilot Feasibility Testing of a Small Randomized Controlled Trial to Evaluate a Telemedicine Stress Management and Lifestyle Group Intervention for Patients With Symptomatic Chronic Hepatitis C

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04198584
Acronym
VC-CBCS
Enrollment
32
Registered
2019-12-13
Start date
2020-04-10
Completion date
2021-02-24
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Brief summary

A pilot feasibility study of a small randomized controlled trial (RCT) comparing a video-conferencing cognitive behavioral coping skills (VC-CBCS) group to standard of care (SC) for symptomatic patients previously diagnosed with chronic hepatitis C to evaluate feasibility, patient satisfaction and differences in symptoms, quality of life and liver markers.

Detailed description

This is a pilot feasibility study of a small randomized controlled trial (RCT) to evaluate a cognitive behavioral coping skills (CBCS) delivered via videoconferencing, referred to as the VC-CBCS compared to standard of care (SC). The study included a representative sample of 32 symptomatic patients who have/had chronic hepatitis C. Patients (n=32) were randomized in a 1:3 ratio to (1) standard of care (SC) or (2) to participate in 14, two hour VC-CBCS sessions. Four groups of patients were randomized and consisted of 7-9 patients each. The groups were as follows: * Group 1: 7 patients with 5 randomized to VC-CBCS and 2 to SC; * Group 2: 9 patients with 7 randomized to VC-CBCS and 2 to SC; * Groups 3 and 4: 8 patients each with 6 randomized to VC-CBCS and 2 to SC each group. Each wave of VC-CBCS patients formed a group to join the Group Facilitator via a WebEx platform on a weekly basis using iPads from their homes. The telehealth intervention provided group-based education, skills and practices involving stress management, coping with symptoms, and support for healthy lifestyle changes. The researchers examined: (1) the feasibility of delivering a group intervention via telehealth technology remotely using iPads, (2) participant satisfaction with the intervention, and (3) whether differences are observed in several outcomes between the two conditions on quality of life, physical and mental symptoms, and liver markers. Participants completed patient-reported outcome (PRO) surveys at four time points during the study, with main outcomes being change from pre-intervention to post-intervention.

Interventions

BEHAVIORALVC-CBCS

A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.

Sponsors

Duke University
CollaboratorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants (n=32) were assigned by 3:1 randomization to VC-CBCS or SC. Participants were recruited in 4 cohorts (Wave 1: n=7, Wave 2: n=9, Waves 3, 4: n=8 each). In Wave 1, 5 participants were randomized to VC-CBCS and 2 to SC. In Wave 2, 7 participants were randomized to VC-CBCS and 2 to SC. In Waves 3 and 4, 6 participants were randomized to VC-CBCS and 2 to SC.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 21 and older; * Medically cleared by hepatology * Patients who are currently or were previously diagnosed with chronic Hepatitis C Viral (HCV) infection; * Evidence of ongoing symptoms, stress, or unhealthy lifestyle habits, defined as a score of greater than or equal to 4 on a scale 0(none) - 10 (severe) on two or more numeric rating scale questions (see Screening Form 1); * Able to read and speak English.

Exclusion criteria

* Decompensated liver disease (Childs Pugh C) judged by hepatologist or recorded in patient medical record; * Life expectancy of \<12 months estimated by hepatologist; * Has had a liver transplant or is on the wait list for a transplant * Severe alcohol or substance use disorder, psychiatric disorder or cognitive impairment that is likely to interfere with the ability to participate in telehealth groups and follow guidelines about group participation as judged by the Hepatology provider or research staff; * Lack of private, quiet space in home in which to participate in VC-CBCS sessions * Unwilling to have intervention sessions audio-recorded

Design outcomes

Primary

MeasureTime frameDescription
Pain Interference Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population.
Sleep Disturbance Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population.
Percentage of VC-CBCS Intervention Condition Participants Retained vs EnrolledSix MonthsPercentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions.
Percentage of Surveys Completed by Participants Who Completed the StudyBaseline (T1) to Week 14 (T4)Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4).
Percentage of Patients Consented Versus ApproachedSix MonthsOne feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study.
Percentage of Participants Consented Versus RandomizedSix MonthsOne feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented.
Percentage of Standard of Care Condition Participants Retained vs EnrolledSix MonthsPercentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study).
Global Health Status Physical Health Mean T-ScoreBaseline (T1), Week 14 (T4)The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.
Global Health Status Mental Health Mean T-ScoreBaseline (T1), Week 14 (T4)The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.
Depression Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population.
Anger Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population.
Anxiety Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6.
Fatigue Mean T-scoreBaseline (T1), Week 14 (T4)The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population.

Secondary

MeasureTime frameDescription
Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a TimeBaseline (T1), Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks Do you do moderate activity for at least 10 minutes at a time? Response options: Yes/No. Percentage is participants who indicate Yes to doing moderate activity for at least 10 minutes at a time
Mean Number of Minutes of Moderate Activity Per WeekBaseline (T1) , Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of moderate activity per week calculated as number of days x number of minutes.
Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a TimeBaseline (T1), Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item Do you do vigorous activity for at least 10 minutes at a time? Response option: Yes/No. Percentage is participants who indicate Yes to doing vigorous activity for at least 10 minutes at a time
Mean Number of Minutes of Vigorous Activity Per WeekBaseline (T1), Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of vigorous activity per week calculated as number of days x number of minutes.
Mean Time Spent Sitting on the WeekdaysBaseline (T1), Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item What is the total number of hours you spend siting on a weekday? The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4.
Mean Time Spent Sitting on the WeekendsBaseline (T1), Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item What is the total number of hours you spend sitting on a weekend day? Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4.
Percentage of Participants Who Reduced Regular Soda Intake by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop. Original 9-point response scale ranged from Never to 6 more more per day. Recoded 9 categories into 5 categories, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4.
Percentage of Participants Who Reduced Diet Soda Intake by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4.
Percentage of Participants Who Reduced Fruit Juice Intake by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4.
Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item In a typical week, how many of your own meals come from fast food restaurants? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4.
Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More DaysBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item On how many days per week do you usually eat a dinner that is prepared at home? 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4.
Change in Weight (Lbs)Baseline (T1) to Week 14 (T4)Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Change in Percent Weight ChangeBaseline (T1) to Week 14 (T4)Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Prescription Drug Misuse Total Mean ScoreBaseline (T1), Week 14 (T4)Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.
Non-prescription Street Drug Use Total Mean ScoreBaseline (T1), Week 14 (T4)Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.
Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean ScoreBaseline (T1), Week 14 (T4)Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency.
Healthy Sleep Behaviors Mean ScoreBaseline (T1), Week 14 (T4)One item In the last month, how often did you engage in healthy sleep behaviors before bedtime? evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors.
Change in Body Mass Index (BMI)Baseline (T1) to Week 14 (T4)Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Perceived Stress Mean ScoreBaseline (T1), Week 14 (T4)The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress.
Coping Skills Confidence Mean ScoreBaseline (T1), Week 14 (T4)The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4.
Participant Satisfaction With VC-CBCS Intervention Mean ScoreBaseline (T1) to Week 14 (T4)After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.
Aspartate Aminotransferase (AST) Mean Score for FemalesBaseline (T1), Week 14 (T4)Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline.
Aspartate Aminotransferase (AST) Mean Score for MalesBaseline (T1), Week 14 (T4)Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline.
Alanine Aminotransferase (ALT) Mean Score for FemalesBaseline (T1), Week 14 (T4)Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.
Alanine Aminotransferase (ALT) Mean Score for MalesBaseline (T1), Week 14 (T4)Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.
Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean ScoreBaseline (T1), Week 14 (T4)Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. During the past month, how would you rate your sleep quality overall? The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality.
Percentage of Overall Medication AdherenceBaseline (T1), Week 14 (T4)Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4.
Alcohol Total Mean ScoreBaseline (T1), Week 14 (T4)Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption.
Percentage of Participants Who Improved Fruit Consumption by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - Over the past 12 months, how often did you eat fruits? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4.
Percentage of Participants Who Improved Vegetable Consumption by One or More CategoriesBaseline (T1) to Week 14 (T4)Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - Over the past 12 months, how often did you eat vegetables? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4.

Other

MeasureTime frameDescription
Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)Baseline (T1), Week 14 (T4)Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29.
Participant Satisfaction With VC-CBCS Telehealth Session Mean ScoreBaseline (T1) to Week 14 (T4)After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study.

Countries

United States

Participant flow

Pre-assignment details

53 participants were approached for study interest; 39 were consented and of those 32 were enrolled.

Participants by arm

ArmCount
VC-CBCS Intervention
The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that included group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy patient Workbook and audio-recorded relaxation techniques.
24
Standard of Care (SC)
Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
8
Total32

Baseline characteristics

CharacteristicVC-CBCS InterventionTotalStandard of Care (SC)
Age, Continuous56 years
STANDARD_DEVIATION 7.5
56 years
STANDARD_DEVIATION 8.5
56 years
STANDARD_DEVIATION 11.4
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants19 Participants5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
10 Participants13 Participants3 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants2 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants7 Participants2 Participants
Race (NIH/OMB)
More than one race
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
16 Participants21 Participants5 Participants
Region of Enrollment
United States
24 Participants32 Participants8 Participants
Sex: Female, Male
Female
5 Participants8 Participants3 Participants
Sex: Female, Male
Male
19 Participants24 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 8
other
Total, other adverse events
0 / 210 / 8
serious
Total, serious adverse events
1 / 210 / 8

Outcome results

Primary

Anger Mean T-score

The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsAnger Mean T-scoreBaseline (T1)51.0 T-score
All PatientsAnger Mean T-scoreWeek 14 (T4)46.5 T-score
Standard of Care (SC)Anger Mean T-scoreBaseline (T1)52.3 T-score
Standard of Care (SC)Anger Mean T-scoreWeek 14 (T4)46.9 T-score
Primary

Anxiety Mean T-score

The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsAnxiety Mean T-scoreBaseline (T1)52.7 T-score
All PatientsAnxiety Mean T-scoreWeek 14 (T4)50.4 T-score
Standard of Care (SC)Anxiety Mean T-scoreBaseline (T1)57.7 T-score
Standard of Care (SC)Anxiety Mean T-scoreWeek 14 (T4)51.2 T-score
Primary

Depression Mean T-score

The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsDepression Mean T-scoreBaseline (T1)52.3 T-score
All PatientsDepression Mean T-scoreWeek 14 (T4)48.6 T-score
Standard of Care (SC)Depression Mean T-scoreBaseline (T1)51.6 T-score
Standard of Care (SC)Depression Mean T-scoreWeek 14 (T4)49.0 T-score
Primary

Fatigue Mean T-score

The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsFatigue Mean T-scoreBaseline (T1)51.9 T-score
All PatientsFatigue Mean T-scoreWeek 14 (T4)48.6 T-score
Standard of Care (SC)Fatigue Mean T-scoreBaseline (T1)50.4 T-score
Standard of Care (SC)Fatigue Mean T-scoreWeek 14 (T4)46.6 T-score
Primary

Global Health Status Mental Health Mean T-Score

The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsGlobal Health Status Mental Health Mean T-ScoreBaseline (T1)46.7 T-score
All PatientsGlobal Health Status Mental Health Mean T-ScoreWeek 14 (T4)49.3 T-score
Standard of Care (SC)Global Health Status Mental Health Mean T-ScoreBaseline (T1)41.9 T-score
Standard of Care (SC)Global Health Status Mental Health Mean T-ScoreWeek 14 (T4)45.9 T-score
Primary

Global Health Status Physical Health Mean T-Score

The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsGlobal Health Status Physical Health Mean T-ScoreBaseline (T1)45.7 T-score
All PatientsGlobal Health Status Physical Health Mean T-ScoreWeek 14 (T4)46.0 T-score
Standard of Care (SC)Global Health Status Physical Health Mean T-ScoreBaseline (T1)41.8 T-score
Standard of Care (SC)Global Health Status Physical Health Mean T-ScoreWeek 14 (T4)48 T-score
Primary

Pain Interference Mean T-score

The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsPain Interference Mean T-scoreBaseline (T1)53.5 T-score
All PatientsPain Interference Mean T-scoreWeek 14 (T4)52.0 T-score
Standard of Care (SC)Pain Interference Mean T-scoreBaseline (T1)55.8 T-score
Standard of Care (SC)Pain Interference Mean T-scoreWeek 14 (T4)54.6 T-score
Primary

Percentage of Participants Consented Versus Randomized

One feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented.

Time frame: Six Months

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Consented Versus Randomized82 percentage of participants
Primary

Percentage of Patients Consented Versus Approached

One feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study.

Time frame: Six Months

ArmMeasureValue (NUMBER)
All PatientsPercentage of Patients Consented Versus Approached74 percentage of participants
Primary

Percentage of Standard of Care Condition Participants Retained vs Enrolled

Percentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study).

Time frame: Six Months

ArmMeasureValue (NUMBER)
All PatientsPercentage of Standard of Care Condition Participants Retained vs Enrolled100 percentage of participants
Primary

Percentage of Surveys Completed by Participants Who Completed the Study

Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4).

Time frame: Baseline (T1) to Week 14 (T4)

Population: Data collection rate is for those who completed the study - 8 Standard of Care and 19 VC-CBCS, total of 27 participants.

ArmMeasureValue (NUMBER)
All PatientsPercentage of Surveys Completed by Participants Who Completed the Study99.4 percentage of surveys completed
Primary

Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled

Percentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions.

Time frame: Six Months

ArmMeasureValue (NUMBER)
All PatientsPercentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled79.2 percentage of participants
Primary

Sleep Disturbance Mean T-score

The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsSleep Disturbance Mean T-scoreBaseline (T1)52.0 T-score
All PatientsSleep Disturbance Mean T-scoreWeek 14 (T4)50.0 T-score
Standard of Care (SC)Sleep Disturbance Mean T-scoreBaseline (T1)50.8 T-score
Standard of Care (SC)Sleep Disturbance Mean T-scoreWeek 14 (T4)46.0 T-score
Secondary

Alanine Aminotransferase (ALT) Mean Score for Females

Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

Time frame: Baseline (T1), Week 14 (T4)

Population: The analytic sample includes 4 females who completed the VC-CBCS intervention and 3 females in Standard of Care. Of these, 1 VC-CBCS Intervention participant had missing data at T4. Of the 3 females in Standard of Care, 2 had missing data at T1 and all 3 participants had missing data at T4.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsAlanine Aminotransferase (ALT) Mean Score for FemalesBaseline (T1)22.0 U/LStandard Deviation 13
All PatientsAlanine Aminotransferase (ALT) Mean Score for FemalesWeek 14 (T4)28.3 U/LStandard Deviation 20
Standard of Care (SC)Alanine Aminotransferase (ALT) Mean Score for FemalesBaseline (T1)13.0 U/LStandard Deviation 0
Secondary

Alanine Aminotransferase (ALT) Mean Score for Males

Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.

Time frame: Baseline (T1), Week 14 (T4)

Population: The analytic sample includes 14 males who completed the VC-CBCS intervention and 5 males in Standard of Care. Of these, 4 VC-CBCS Intervention participants had missing data at T1 and 5 at T4. Of the 5 males in Standard of Care, 1 had missing data at T1 and 2 had missing data at T4.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsAlanine Aminotransferase (ALT) Mean Score for MalesBaseline (T1)34.6 U/LStandard Deviation 23
All PatientsAlanine Aminotransferase (ALT) Mean Score for MalesWeek 14 (T4)36.9 U/LStandard Deviation 24.1
Standard of Care (SC)Alanine Aminotransferase (ALT) Mean Score for MalesBaseline (T1)33.0 U/LStandard Deviation 10.3
Standard of Care (SC)Alanine Aminotransferase (ALT) Mean Score for MalesWeek 14 (T4)28.0 U/LStandard Deviation 12.5
Secondary

Alcohol Total Mean Score

Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption.

Time frame: Baseline (T1), Week 14 (T4)

Population: 1 VC-CBCS Intervention participant with missing data at T1.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsAlcohol Total Mean ScoreBaseline (T1)1.39 score on a scaleStandard Deviation 2.43
All PatientsAlcohol Total Mean ScoreWeek 14 (T4)0.95 score on a scaleStandard Deviation 2.27
Standard of Care (SC)Alcohol Total Mean ScoreBaseline (T1)0.13 score on a scaleStandard Deviation 0.35
Standard of Care (SC)Alcohol Total Mean ScoreWeek 14 (T4)0.25 score on a scaleStandard Deviation 0.71
Secondary

Aspartate Aminotransferase (AST) Mean Score for Females

Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline.

Time frame: Baseline (T1), Week 14 (T4)

Population: The analytic sample includes 4 females who completed the VC-CBCS intervention and 3 females in Standard of Care. Of these, 1 VC-CBCS Intervention participant had missing data at T4. Of the 3 females in Standard of Care, 2 had missing data at T1 and all 3 participants had missing data at T4.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsAspartate Aminotransferase (AST) Mean Score for FemalesBaseline (T1)28.0 U/LStandard Deviation 8.91
All PatientsAspartate Aminotransferase (AST) Mean Score for FemalesWeek 14 (T4)31.0 U/LStandard Deviation 8.89
Standard of Care (SC)Aspartate Aminotransferase (AST) Mean Score for FemalesBaseline (T1)23.0 U/LStandard Deviation 0
Secondary

Aspartate Aminotransferase (AST) Mean Score for Males

Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline.

Time frame: Baseline (T1), Week 14 (T4)

Population: The analytic sample includes 14 males who completed the VC-CBCS intervention and 5 males in Standard of Care. Of these, 4 VC-CBCS Intervention participants had missing data at T1 and 5 at T4. Of the 5 males in Standard of Care, 1 had missing data at T1 and 2 had missing data at T4.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsAspartate Aminotransferase (AST) Mean Score for MalesBaseline (T1)34.7 U/LStandard Deviation 11.2
All PatientsAspartate Aminotransferase (AST) Mean Score for MalesWeek 14 (T4)30.0 U/LStandard Deviation 8.39
Standard of Care (SC)Aspartate Aminotransferase (AST) Mean Score for MalesBaseline (T1)36.5 U/LStandard Deviation 17.3
Standard of Care (SC)Aspartate Aminotransferase (AST) Mean Score for MalesWeek 14 (T4)45.3 U/LStandard Deviation 31.8
Secondary

Change in Body Mass Index (BMI)

Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)

ArmMeasureValue (MEAN)Dispersion
All PatientsChange in Body Mass Index (BMI)-0.53 kg/m^2Standard Deviation 2.28
Standard of Care (SC)Change in Body Mass Index (BMI)0.23 kg/m^2Standard Deviation 0.83
Secondary

Change in Percent Weight Change

Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)

ArmMeasureValue (MEAN)Dispersion
All PatientsChange in Percent Weight Change0.91 percent of weight changeStandard Deviation 5.65
Standard of Care (SC)Change in Percent Weight Change-0.23 percent of weight changeStandard Deviation 1.91
Secondary

Change in Weight (Lbs)

Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)

ArmMeasureValue (MEAN)Dispersion
All PatientsChange in Weight (Lbs)-2.67 poundsStandard Deviation 13.7
Standard of Care (SC)Change in Weight (Lbs)0.0 poundsStandard Deviation 3.56
Secondary

Coping Skills Confidence Mean Score

The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsCoping Skills Confidence Mean ScoreBaseline (T1)2.18 score on a scale
All PatientsCoping Skills Confidence Mean ScoreWeek 14 (T4)2.74 score on a scale
Standard of Care (SC)Coping Skills Confidence Mean ScoreBaseline (T1)2.16 score on a scale
Standard of Care (SC)Coping Skills Confidence Mean ScoreWeek 14 (T4)2.38 score on a scale
Secondary

Healthy Sleep Behaviors Mean Score

One item In the last month, how often did you engage in healthy sleep behaviors before bedtime? evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors.

Time frame: Baseline (T1), Week 14 (T4)

Population: 2 Standard of Care participants were missing data for this variable at T4

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsHealthy Sleep Behaviors Mean ScoreWeek 14 (T4)2.42 score on a scaleStandard Deviation 0.84
All PatientsHealthy Sleep Behaviors Mean ScoreBaseline (T1)1.37 score on a scaleStandard Deviation 1.26
Standard of Care (SC)Healthy Sleep Behaviors Mean ScoreBaseline (T1)2.13 score on a scaleStandard Deviation 0.99
Standard of Care (SC)Healthy Sleep Behaviors Mean ScoreWeek 14 (T4)2.17 score on a scaleStandard Deviation 1.33
Secondary

Mean Number of Minutes of Moderate Activity Per Week

Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of moderate activity per week calculated as number of days x number of minutes.

Time frame: Baseline (T1) , Week 14 (T4)

Population: 5 participants with missing data for this variable (4 VC-CBCS intervention participants, 1 Standard of Care)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsMean Number of Minutes of Moderate Activity Per WeekBaseline (T1)314 minutesStandard Deviation 556
All PatientsMean Number of Minutes of Moderate Activity Per WeekWeek 14 (T4)528 minutesStandard Deviation 808
Standard of Care (SC)Mean Number of Minutes of Moderate Activity Per WeekBaseline (T1)87.9 minutesStandard Deviation 120
Standard of Care (SC)Mean Number of Minutes of Moderate Activity Per WeekWeek 14 (T4)170 minutesStandard Deviation 257
Secondary

Mean Number of Minutes of Vigorous Activity Per Week

Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of vigorous activity per week calculated as number of days x number of minutes.

Time frame: Baseline (T1), Week 14 (T4)

Population: 2 participants missing data for this variable (1 VC-CBCS Intervention, 1 Standard of Care)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsMean Number of Minutes of Vigorous Activity Per WeekBaseline (T1)241 total minutes in a weekStandard Deviation 457
All PatientsMean Number of Minutes of Vigorous Activity Per WeekWeek 14 (T4)235 total minutes in a weekStandard Deviation 513
Standard of Care (SC)Mean Number of Minutes of Vigorous Activity Per WeekBaseline (T1)55.7 total minutes in a weekStandard Deviation 74.4
Standard of Care (SC)Mean Number of Minutes of Vigorous Activity Per WeekWeek 14 (T4)17.1 total minutes in a weekStandard Deviation 34
Secondary

Mean Time Spent Sitting on the Weekdays

Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item What is the total number of hours you spend siting on a weekday? The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4.

Time frame: Baseline (T1), Week 14 (T4)

Population: 1 Standard of Care participant missing data for this variable

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsMean Time Spent Sitting on the WeekdaysBaseline (T1)8.95 hoursStandard Deviation 3.44
All PatientsMean Time Spent Sitting on the WeekdaysWeek 14 (T4)7.0 hoursStandard Deviation 2.28
Standard of Care (SC)Mean Time Spent Sitting on the WeekdaysBaseline (T1)6.57 hoursStandard Deviation 4.08
Standard of Care (SC)Mean Time Spent Sitting on the WeekdaysWeek 14 (T4)7.0 hoursStandard Deviation 2.31
Secondary

Mean Time Spent Sitting on the Weekends

Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item What is the total number of hours you spend sitting on a weekend day? Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsMean Time Spent Sitting on the WeekendsBaseline (T1)7.68 hoursStandard Deviation 3.53
All PatientsMean Time Spent Sitting on the WeekendsWeek 14 (T4)4.22 hoursStandard Deviation 2.26
Standard of Care (SC)Mean Time Spent Sitting on the WeekendsBaseline (T1)6.0 hoursStandard Deviation 3.66
Standard of Care (SC)Mean Time Spent Sitting on the WeekendsWeek 14 (T4)6.43 hoursStandard Deviation 3.1
Secondary

Non-prescription Street Drug Use Total Mean Score

Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsNon-prescription Street Drug Use Total Mean ScoreBaseline (T1)1.37 score on a scaleStandard Deviation 1.71
All PatientsNon-prescription Street Drug Use Total Mean ScoreWeek 14 (T4)0.95 score on a scaleStandard Deviation 1.47
Standard of Care (SC)Non-prescription Street Drug Use Total Mean ScoreBaseline (T1)0.88 score on a scaleStandard Deviation 1.36
Standard of Care (SC)Non-prescription Street Drug Use Total Mean ScoreWeek 14 (T4)0.13 score on a scaleStandard Deviation 0.35
Secondary

Participant Satisfaction With VC-CBCS Intervention Mean Score

After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.

Time frame: Baseline (T1) to Week 14 (T4)

Population: Participants randomized to Standard of Care received no intervention and did not complete survey.

ArmMeasureValue (MEAN)Dispersion
All PatientsParticipant Satisfaction With VC-CBCS Intervention Mean Score4.23 score on a scaleStandard Deviation 0.5
Secondary

Perceived Stress Mean Score

The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)
All PatientsPerceived Stress Mean ScoreBaseline (T1)24.2 score on a scale
All PatientsPerceived Stress Mean ScoreWeek 14 (T4)20.6 score on a scale
Standard of Care (SC)Perceived Stress Mean ScoreBaseline (T1)23.9 score on a scale
Standard of Care (SC)Perceived Stress Mean ScoreWeek 14 (T4)21.8 score on a scale
Secondary

Percentage of Overall Medication Adherence

Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4.

Time frame: Baseline (T1), Week 14 (T4)

Population: 7 VC-CBCS Intervention participants were excluded from the analysis because they were not prescribed daily medications at Baseline (T1). Two of the 12 VC-CBCS participants and 4 of the Standard of Care participants were missing data for this variable at T4.

ArmMeasureGroupValue (NUMBER)
All PatientsPercentage of Overall Medication AdherenceBaseline (T1)85.2 percentage of medication adherence
All PatientsPercentage of Overall Medication AdherenceWeek 14 (T4)92.8 percentage of medication adherence
Standard of Care (SC)Percentage of Overall Medication AdherenceBaseline (T1)96.9 percentage of medication adherence
Standard of Care (SC)Percentage of Overall Medication AdherenceWeek 14 (T4)89.8 percentage of medication adherence
Secondary

Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time

Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks Do you do moderate activity for at least 10 minutes at a time? Response options: Yes/No. Percentage is participants who indicate Yes to doing moderate activity for at least 10 minutes at a time

Time frame: Baseline (T1), Week 14 (T4)

Population: 1 VC-CBCS Intervention participant with missing data at T1.

ArmMeasureGroupValue (NUMBER)
All PatientsPercentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a TimeBaseline (T1)73.7 percentage of participants
All PatientsPercentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a TimeWeek 14 (T4)78.9 percentage of participants
Standard of Care (SC)Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a TimeBaseline (T1)50.0 percentage of participants
Standard of Care (SC)Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a TimeWeek 14 (T4)87.5 percentage of participants
Secondary

Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time

Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item Do you do vigorous activity for at least 10 minutes at a time? Response option: Yes/No. Percentage is participants who indicate Yes to doing vigorous activity for at least 10 minutes at a time

Time frame: Baseline (T1), Week 14 (T4)

Population: 1 VC-CBCS Intervention participant missing data for this variable

ArmMeasureGroupValue (NUMBER)
All PatientsPercentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a TimeBaseline (T1)42.1 percentage of participants
All PatientsPercentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a TimeWeek 14 (T4)47.4 percentage of participants
Standard of Care (SC)Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a TimeBaseline (T1)50.0 percentage of participants
Standard of Care (SC)Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a TimeWeek 14 (T4)25.0 percentage of participants
Secondary

Percentage of Participants Who Improved Fruit Consumption by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - Over the past 12 months, how often did you eat fruits? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 1 Standard of Care participant missing data for this variable

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Improved Fruit Consumption by One or More Categories47.0 percentage of patients
Standard of Care (SC)Percentage of Participants Who Improved Fruit Consumption by One or More Categories43.0 percentage of patients
Secondary

Percentage of Participants Who Improved Vegetable Consumption by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - Over the past 12 months, how often did you eat vegetables? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 1 Standard of Care participant missing data for this variable

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Improved Vegetable Consumption by One or More Categories16 percentage of participants
Standard of Care (SC)Percentage of Participants Who Improved Vegetable Consumption by One or More Categories14 percentage of participants
Secondary

Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days

Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item On how many days per week do you usually eat a dinner that is prepared at home? 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: Three participants were missing data for this variable (2 VC-CBCS Intervention participants, 1 Standard of Care participant)

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days35 percentage of participants
Standard of Care (SC)Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days0 percentage of participants
Secondary

Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 2 Standard of Care participants missing data for this variable

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Reduced Diet Soda Intake by One or More Categories5 percentage of participants
Standard of Care (SC)Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories17 percentage of participants
Secondary

Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 1 Standard of Care participant missing data for this variable

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Reduced Fruit Juice Intake by One or More Categories16 percentage of participants
Standard of Care (SC)Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories29 percentage of participants
Secondary

Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item In a typical week, how many of your own meals come from fast food restaurants? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 3 participants were missing data for this variable (1 VC-CBCS Intervention participant, 2 Standard of Care participants)

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories39 percentage of participants
Standard of Care (SC)Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories17 percentage of participants
Secondary

Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories

Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop. Original 9-point response scale ranged from Never to 6 more more per day. Recoded 9 categories into 5 categories, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4.

Time frame: Baseline (T1) to Week 14 (T4)

Population: 3 participants missing data for this variable (2 VC-CBCS Intervention participants, 1 Standard of Care participant)

ArmMeasureValue (NUMBER)
All PatientsPercentage of Participants Who Reduced Regular Soda Intake by One or More Categories35 percentage of participants
Standard of Care (SC)Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories14 percentage of participants
Secondary

Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score

Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsPittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean ScoreBaseline (T1)1.05 score on a scaleStandard Deviation 1.22
All PatientsPittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean ScoreWeek 14 (T4)1.26 score on a scaleStandard Deviation 1.37
Standard of Care (SC)Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean ScoreBaseline (T1)1.38 score on a scaleStandard Deviation 1.3
Standard of Care (SC)Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean ScoreWeek 14 (T4)0.75 score on a scaleStandard Deviation 1.04
Secondary

Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score

Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. During the past month, how would you rate your sleep quality overall? The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality.

Time frame: Baseline (T1), Week 14 (T4)

Population: 1 Standard of Care participant missing data for this variable at T4

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsPittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean ScoreBaseline (T1)1.32 score on a scaleStandard Deviation 0.82
All PatientsPittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean ScoreWeek 14 (T4)1.05 score on a scaleStandard Deviation 0.52
Standard of Care (SC)Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean ScoreBaseline (T1)1.13 score on a scaleStandard Deviation 0.64
Standard of Care (SC)Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean ScoreWeek 14 (T4)0.71 score on a scaleStandard Deviation 0.76
Secondary

Prescription Drug Misuse Total Mean Score

Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.

Time frame: Baseline (T1), Week 14 (T4)

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsPrescription Drug Misuse Total Mean ScoreBaseline (T1)0.11 score on a scaleStandard Deviation 0.32
All PatientsPrescription Drug Misuse Total Mean ScoreWeek 14 (T4)0.11 score on a scaleStandard Deviation 0.32
Standard of Care (SC)Prescription Drug Misuse Total Mean ScoreBaseline (T1)0.0 score on a scaleStandard Deviation 0
Standard of Care (SC)Prescription Drug Misuse Total Mean ScoreWeek 14 (T4)0.0 score on a scaleStandard Deviation 0
Other Pre-specified

Participant Satisfaction With VC-CBCS Telehealth Session Mean Score

After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study.

Time frame: Baseline (T1) to Week 14 (T4)

Population: Participants randomized to Standard of Care received no intervention and did not complete survey.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsParticipant Satisfaction With VC-CBCS Telehealth Session Mean ScoreWeek 13.91 score on a scaleStandard Deviation 0.68
All PatientsParticipant Satisfaction With VC-CBCS Telehealth Session Mean ScoreWeek 144.5 score on a scaleStandard Deviation 0.38
Other Pre-specified

Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)

Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29.

Time frame: Baseline (T1), Week 14 (T4)

Population: T1: Data from 1 Standard of Care participant were excluded due to nontraditional sleep schedule. Data from 5 VC-CBCS Intervention participants were excluded due to missing data, nontraditional sleep schedules, and/or noncompliance with sample collection instructions.~T4: Data from 2 Standard of Care participants and 7 VC-CBCS Intervention participants were excluded due to missing data, nontraditional sleep schedules, and/or noncompliance with sample collection instructions.

ArmMeasureGroupValue (MEAN)Dispersion
All PatientsSalivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)Baseline (T1)1.01 ug/dLStandard Deviation 0.54
All PatientsSalivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)Week 14 (T4)0.71 ug/dLStandard Deviation 0.23
Standard of Care (SC)Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)Baseline (T1)1.18 ug/dLStandard Deviation 0.65
Standard of Care (SC)Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)Week 14 (T4)0.83 ug/dLStandard Deviation 0.46

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026